How A Duty To Spend Wisely On Worker Benefits Could Loosen Pbms Grip On Drug Prices
A Fiduciary Duty to Spend Wisely: Undermining PBMs and Lowering Drug Prices
The opaque pricing structures and immense profits enjoyed by Pharmacy Benefit Managers (PBMs) have become a significant barrier to affordable prescription drugs in the United States. While PBMs claim to negotiate lower prices on behalf of employers and health plans, evidence increasingly suggests their business model often exacerbates, rather than alleviates, drug costs for consumers and the entities they represent. A critical, yet under-explored, avenue for reining in PBMs’ influence and driving down drug prices lies in the rigorous application of a fiduciary duty to spend wisely on worker benefits. This obligation, inherent in the management of employee healthcare plans, demands transparency, cost-effectiveness, and an unwavering focus on securing the best value for the ultimate beneficiaries – the employees. By imposing this duty, stakeholders can force a recalibration of PBM practices, pushing them to prioritize genuine cost savings over their own profit margins.
At its core, a fiduciary duty imposes a legal and ethical obligation to act in the best interests of another party, exercising utmost care, loyalty, and good faith. When applied to employers and health plan sponsors who provide prescription drug benefits, this duty translates into a responsibility to ensure that every dollar spent on these benefits achieves maximum value. This means scrutinizing the negotiated rebates, administrative fees, and formulary management practices of PBMs with an unwavering commitment to cost containment and patient well-being. Currently, the convoluted nature of PBM contracts and the significant rebates they secure often obscure the true net cost of medications. A fiduciary duty would compel employers and plan sponsors to demand greater transparency, demanding to know the actual price paid for drugs after rebates and fees. This transparency would expose the inflated list prices that PBMs use as a negotiating tool, effectively allowing them to capture a portion of the negotiated savings as profit. Without this direct line of sight into net costs, it becomes exceedingly difficult for employers to assess whether their PBM is truly acting in their best interest or simply maximizing its own revenue.
The concept of "best price" is central to how PBMs operate. They negotiate substantial rebates from drug manufacturers in exchange for preferred formulary placement. While seemingly beneficial, this system can incentivize PBMs to favor higher-priced drugs that offer larger rebates, even if lower-cost alternatives exist. A fiduciary duty would require plan sponsors to actively challenge this incentive structure. Instead of accepting the status quo, they would be compelled to investigate whether their PBM is prioritizing drugs that yield the highest rebates for the PBM, rather than the lowest net cost for the plan. This would involve conducting independent analyses of drug pricing, comparing net costs across different PBMs, and potentially exploring direct contracting with manufacturers or alternative dispensing models. The fiduciary obligation necessitates a proactive approach, moving beyond passive reliance on PBM assurances and engaging in diligent oversight.
Furthermore, the "spread pricing" model, where PBMs charge health plans more for a drug than they reimburse the pharmacy, represents another area where a fiduciary duty to spend wisely can exert significant pressure. PBMs often profit from this spread, further inflating the cost of prescription drugs. A fiduciary duty would necessitate a deep dive into the PBM’s revenue streams, demanding to understand how much of the drug cost is passed through to the plan versus retained by the PBM. This would involve auditing PBM contracts and claims data to identify instances of egregious spread pricing. Armed with this information, employers could then negotiate more favorable contract terms, demand pass-through of all negotiated rebates, or even seek alternative PBMs that operate on a transparent, fee-for-service model. The onus would be on the PBM to demonstrate that its pricing practices are not only competitive but also aligned with the fiduciary obligation of the plan sponsor to obtain the best possible value.
The lack of competition among PBMs, with a few dominant players controlling a vast majority of the market, further entrenches their power. This oligopolistic structure reduces the incentive for PBMs to genuinely compete on cost and transparency. However, a robust application of fiduciary duty can create a powerful counterforce. By actively seeking out and evaluating alternative PBMs, or even considering self-administration of pharmacy benefits where feasible, employers can foster a more competitive landscape. The fiduciary obligation to spend wisely compels a thorough market analysis, not just a superficial comparison of PBM offerings. This means understanding the total cost of ownership, including hidden fees, administrative burdens, and the long-term impact of formulary decisions on member health outcomes.
The impact of PBMs on generic drug utilization is another critical area where fiduciary duty can drive change. While PBMs often claim to promote generic substitution, their rebate-driven model can, at times, disincentivize this. If a brand-name drug offers a larger rebate, a PBM might subtly steer members towards it, even if a cost-effective generic is available. A fiduciary duty would require employers to ensure their PBM is actively and aggressively promoting generic utilization, not just as a compliance exercise but as a primary cost-saving strategy. This would involve examining formulary designs, patient education initiatives, and the PBM’s incentives for pharmacists to promote generics. The ultimate goal would be to ensure that the PBM’s actions are consistently aligned with maximizing savings for the plan, which invariably means prioritizing generics.
Beyond direct pricing and rebate negotiations, PBMs exert influence through their control over pharmacy networks and mail-order programs. A fiduciary duty to spend wisely would extend to scrutinizing these aspects as well. Are the contracted pharmacy rates truly competitive? Are mail-order programs offering genuine savings or are they merely another profit center for the PBM? Employers would need to investigate the cost-effectiveness of their chosen pharmacy network, comparing reimbursement rates to market benchmarks and assessing the accessibility and convenience of the network for their employees. Similarly, the cost and efficacy of mail-order programs would need to be evaluated to ensure they are delivering on their promise of cost savings and convenience.
The legal framework surrounding PBMs is often criticized for its complexity and lack of regulatory oversight. However, the fiduciary duty to spend wisely offers a potent, existing legal and ethical lever for change. Employers and health plan sponsors already have a legal obligation to manage their employee benefits responsibly. By framing the push for PBM reform through the lens of this fiduciary duty, stakeholders can leverage existing legal principles to demand greater accountability. This means shifting the narrative from a request for PBM cooperation to a demand for PBM compliance with the fiduciary obligations of their clients. Legal counsel can play a crucial role in this by advising employers on how to structure PBM contracts to align with fiduciary principles and by advocating for greater transparency and accountability in PBM operations.
The long-term implications of a lax approach to PBM oversight are substantial. Unchecked PBM profits contribute to rising healthcare costs, making it increasingly difficult for employers to offer competitive benefits and for employees to afford essential medications. A failure to address this issue through the rigorous application of a fiduciary duty to spend wisely on worker benefits not only harms current employees but also undermines the long-term sustainability of employer-sponsored healthcare. By embracing this duty, employers can actively dismantle the PBM stranglehold on drug prices, ushering in an era of greater transparency, genuine cost savings, and ultimately, more affordable prescription medications for all. The path forward requires a commitment to diligent oversight, unwavering transparency, and a fundamental understanding that the ultimate beneficiaries of these benefits, the employees, deserve nothing less than the most cost-effective and value-driven healthcare solutions available.
